Inflammatory Bowel Diseases: World Drug Market 2011-2021

NEW YORK, Aug. 22, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Inflammatory Bowel Diseases: World Drug Market 2011-2021

http://www.reportlinker.com/p0595028/Inflammatory-Bowel-Diseases-World-Drug-Market-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

How will the market for inflammatory bowel disease (IBD) treatments perform from 2011? Our new report shows you potential pharmaceutical revenues to 2021, discussing opportunities and market prospects.

Discover potential IBD drug revenues at total world, submarket, product and national levels. Through our research and analysis we aim to save you time and help in your decisions.

See how drugs such as Remicade, Humira, Cimzia, Asacol, Pentasa and Entocort can perform to 2021, finding potential revenues. How will competition affect the bowel disorder drug market?

Our study covers Warner Chilcott, Shire, Prometheus, Kyorin, Merck, UCB, Schering-Plough, J&J and other companies. Discover commercial prospects for biological and non-biological drugs for IBD. Receive data you need.

There is a strong R&D pipeline for treating Crohn's disease and ulcerative colitis. We cover monoclonal antibodies, small molecules, antibiotics and other agents. Find R&D trends.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Analysis with revenues, future growth rates, market shares, opinions and discussions

In our report you find revenue forecasts, growth rates, market shares, a SWOT/STEP review, an R&D review and opinions from our survey. You receive 78 tables and charts and three research interviews (shown in the accompanying lists).

Inflammatory Bowel Diseases: World Drug Market 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:

• Find revenue predictions to 2021 for the world IBD drug market and its submarkets, seeing revenue growth

• Discover revenue forecasts to 2021 for leading products, assessing market potentials

• See revenue forecasts to 2021 for leading national markets - US, Japan, Germany, France, UK, Spain, Italy, China and India

• Assess companies providing IBD treatments, discovering their activities and outlooks

• Find out how the IBD drug industry can change and adapt from 2011 to 2021

• Investigate competition and opportunities influencing the industry and market

• See what will stimulate and restrain the industry and market from 2011

• Review the R&D pipeline for IBD, assessing its potential

• Investigate commercial requirements, identifying therapeutic needs and opportunities

• Analyse opportunities and challenges for established and emerging companies

• View opinions from our survey, receiving three full interview transcripts.

There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions on inflammatory bowel diseases, helping you to stay ahead.

Order our report now to gain industry and market analysis for bowel disorders

Our report is for everybody interested in industry and market analysis for treating inflammatory bowel diseases. Find trends and answers. Don't miss out - please order our report now.

Table of Contents

1. Executive Summary

1.1 Inflammatory Bowel Disease Market Overview

1.2 Aims, Scope and Format of the Report

1.3 Chapter Outlines

1.4 Research and Analysis Methods

2. Introduction to the Inflammatory Bowel Disease Market

2.1 Definition of Inflammatory Bowel Disease (IBD)

2.2 Types of IBD

2.3 Signs, Symptoms and Associated Conditions

2.3.1 Bleeding Ulcers, Fistulae, Bowel Perforations, Toxic Megacolon

2.3.2 Pyoderma Gangrenosum

2.3.3 Primary Sclerosing Cholagitis

2.3.4 Malnutrition, Poor Nutrient Absorption and Stunting

2.4 Ulcerative Colitis

2.5 Crohn's Disease

2.6 Indeterminate Colitis: Distinguishing Crohn's Disease from Ulcerative Colitis

2.7 What Causes Inflammatory Bowel Disease?

2.7.1 Genetic Factors

2.7.2 Environmental Factors

2.8 How Common is Inflammatory Bowel Disease?

2.8.1 Geographical Variations in Rates of IBD

2.9 Socioeconomic Costs of IBD

2.9.1 The Individual Cost of IBD

3. Treatments for Inflammatory Bowel Diseases

3.1 Treatment Goals

3.2 Drug Classes Used in IBD Treatment

3.2.1 Aminosalicylates

3.2.2 Corticosteroids

3.2.3 Immunomodulators

3.2.4 Monoclonal Antibodies

3.3 Surgery

3.3.1 Surgery for Ulcerative Colitis

3.3.2 Surgery for Crohn's Disease

3.4 Alternative Treatments

3.4.1 Faecal Bateriotherapy and Pre/Probiotics

3.4.2 Helminthic Therapy

3.4.3 Complementary Medicine

3.5 Treatment Protocol

3.5.1 Recent Trial Data

4. The World Inflammatory Bowel Disease Market, 2011-2021

4.1 Non-Biological Drugs

4.1.1 IBD-Specific Drugs (Intestinal Anti-Inflammatories)

4.1.2 Drugs Not Specific to IBD

4.2 Biological Drugs

4.3 Total IBD Market

4.4 Market Shares by Disease Type

4.5 Market Forecast: World Inflammatory Bowel Disease Sales, 2011-2021

4.6 Market Forecast: World Sales by Disease Type, 2011-2021

4.7 Market Forecast: World Sales by Therapy Type, 2011-2021

5. Market Prospects for Leading IBD Drugs, 2011-2021

5.1 Intestinal Anti-Inflammatory Drugs (IAIs/Non Biological Drugs)

5.2 Asacol (Mesalazine) - Warner Chilcott

5.2.1 Asacol: Information

5.2.2 Asacol Forecast and Analysis, 2011-2021

5.3 Pentasa (mesalazine) - Shire/Ferring

5.3.1 Pentasa: Information

5.3.2 Pentasa: Forecast and Analysis, 2011-2021

5.4 Entocort (budenoside) - AstraZeneca, Prometheus

5.4.1 Entocort: Information

5.4.2 Entocort: Forecast and Analysis, 2011-2021

5.5 Lialda (mesalazine) - Shire

5.5.1 Lialda: Information

5.5.2 Lialda: Forecast and Analysis, 2011-2021

5.6 Salofalk (mesalazine) - Dr. Falk

5.6.1 Salofalk: Information

5.6.2 Salofalk: Forecast and Analysis, 2011-2021

5.7 Other IAIs

5.8 Biological Drugs Used to Treat IBD

5.9 Remicade (infliximab) - Merck & Co., Schering-Plough, Johnson & Johnson

5.9.1 Remicade: Information

5.9.2 Remicade: Forecast and Analysis, 2011-2021

5.10 Humira (adalimumab) - Abbott

5.10.1 Humira: information

5.10.2 Humira: Forecast and Analysis, 2011-2021

5.11 Cimzia (certolizumab pegol) - UCB

5.11.1 Cimzia: Information

5.11.2 Cimzia: Forecast and Analysis, 2011-2021

5.12 Tysabri (natalizumab) - Biogen Idec/Elan

5.12.1 Tysabri: Information

5.12.2 Tysabri: Forecast and Analysis, 2011-2021

6. The R&D Pipeline for Inflammatory Bowel Disease, 2011-2021

6.1 Monoclonal Antibodies

6.1.1 HuZAF (fontolizumab) - Biogen Idec

6.1.2 Stelara (uskinamab) - Johnson & Johnson

6.1.3 Vedolizumab (MLN02) - Takeda

6.1.4 Simponi (golimumab) - Johnson & Johnson

6.2 Small Molecules

6.2.1 Tetomilast - Otsuka

6.2.2 Firategrast -GlaxoSmithKline

6.3 Antibiotics

6.3.1 Rifaximin - Salix Pharmaceuticals

6.3.2 Myconda - Giaconda

6.4 Nicotine and Buproprion

6.5 Alicaforsen - Isis

6.6 Alequel - Enzo

6.7 MAP Vaccine

6.8 Autologous Stem Cell Transplantation for Crohn's Disease

6.9 Technologies That Deliver Drugs to Affected Parts of the GI Tract

7. Drivers and Restraints in the Inflammatory Bowel Disease Drug Market, 2011-2021

7.1 SWOT Analysis of the IBD Market

7.2 Market Drivers

7.2.1 Increasing Disease Incidence

7.2.2 Better Diagnosis

7.2.3 Nature of the Disease

7.2.4 Delivery Systems

7.2.5 Biological Drugs

7.3 Market Restraints

7.3.1 Lack of Understanding of Disease Aetiology

7.3.2 Compliance

7.3.3 Limits of Biologics

7.3.4 A Cure or Vaccine

8. Leading National Markets for Inflammatory Bowel Disease Treatments, 2011-2021

8.1 Leading National Markets for IBD, 2011-2021

8.2 The US IBD Market: Forecast and Outlook, 2011-2021

8.3 The Japanese IBD Market: Forecast and Outlook, 2011-2021

8.4 Leading European IBD Markets: Forecasts and Outlook, 2011-2021

8.4.1 The German IBD Market, 2011-2021

8.4.2 The French IBD Market, 2011-2021

8.4.3 The Italian IBD Market, 2011-2021

8.4.4 The Spanish IBD Market, 2011-2021

8.4.5 The UK IBD Market, 2011-2021

8.5 Top 5 EU Markets for IBD Drugs, 2011-2021

8.6 IBD Drugs in Emerging Markets

8.6.1 Chinese IBD Market: Forecast and Outlook, 2011-2021

8.6.2 Indian IBD Market: Forecast and Outlook, 2011-2021

8.7 IBD Revenues from the Two Leading Emerging Markets, 2011-2021

8.8 Revenues for IBD Drugs in the Rest of the World: Forecast and Outlook, 2011-2021

8.9 Global IBD Market by Region, 2010

9. Leading Companies in the Industry and Market

9.1 The Largest Companies by Revenue in the Intestinal Anti-Inflammatory Market

9.2 Warner Chilcott

9.3 Shire Pharmaceuticals Group

9.4 Prometheus Laboratories

9.5 Ferring Pharmaceuticals

9.6 Kyorin Pharmaceutical Co.

10. Research Interviews from Our Survey

10.1 Professor John Hermon-Taylor, King's College London

10.1.1 The Significance of MAP in Crohn's

10.1.2 Rising Incidence of IBD

10.1.3 Defining IBD

10.1.4 Timeframe of MAP Vaccine

10.1.5 Antibiotic Activity of Other Crohn's Treatments

10.1.6 Alternative Treatments

10.1.7 Ethics of Crohn's Drug Development

10.1.8 The Impact of a Vaccine on the Market

10.1.9 On Claims that MAP is Not Implicated in CD

10.2 Marco Greco, Chairman, European Federation of Crohn's and Ulcerative Colitis Associations

10.2.1 Public Awareness of IBD

10.2.2 The Differences between European Countries

10.2.3 Drug Companies and Their Involvement in Awareness Campaigns

10.2.4 Unmet Medical Needs

10.3 Professor Thomas Barody, Director, Centre for Digestive Diseases, Sydney

10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology

10.3.2 IBD and HIV/AIDS

10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments

10.3.4 Potential Cure?

10.3.5 Remicade and MAP

10.3.6 Genotyping

10.3.7 Crohn's vs. Colitis

10.3.8 Future Therapies

10.3.9 The Potential and Future of Myoconda

11. Conclusions

11.1 IBD Market to Grow from 2011 to 2021

11.2 Non-Biologic Treatments

11.3 Biologic Treatments

11.4 Improvements Needed in IBD Treatments

11.5 Future IBD Treatments: R&D Efforts Promising

11.6 The IBD Sector: Looking to the Future Confidently

List of Tables

Table 2.1 World Incidence Rates for IBD, 2011

Table 2.2 Geographical Variations in the Incidence of IBD, 2010

Table 2.3 Misdiagnosis of IBD in Developing Countries, 2011

Table 3.1 Drug Types Used to treat IBD, 2011

Table 3.2 Drugs Used to Treat IBD, 2011

Table 4.1 Total IBD Market Forecast with Main Submarkets ($m), 2010-2021

Table 4.2 Global IBD Market Forecast ($m), 2010-2021

Table 4.3 World IBD Market Forecasts by Disease ($m), 2010-2021

Table 4.4 World IBD Market Shares (%) and Revenues ($m) by Disease Type, 2010, 2015 and 2021

Table 4.5 IBD Drug Market Forecasts ($m) by Therapy Type, 2010-2021

Table 5.1 Top 5 IAI Drugs ($m), 2010

Table 5.2 World Asacol Revenue Forecast ($m), 2010-2021

Table 5.3 World Pentasa Revenue Forecast ($m), 2010-2021

Table 5.4 World Entocort Revenue Forecast ($m), 2010-2021

Table 5.5 World Lialda Revenue Forecast ($m), 2010-2021

Table 5.6 World Salofalk Revenue Forecast ($m), 2010-2021

Table 5.7 Market Forecast for top IAI Drugs ($m), 2010-2021

Table 5.8 World Remicade Revenue Forecast ($m), 2010-2021

Table 5.9 World Humira Revenue Forecast ($m), 2010-2021

Table 5.10 World Cimzia Revenue Forecast ($m), 2010-2021

Table 5.11 World Tysabri Revenue Forecast ($m), 2010-2021

Table 5.12 Market Forecasts ($m) for Top Biological IBD Drugs, 2010-2021

Table 5.13 World IBD Drug Market Forecasts ($m) by Drug Class, 2010-2021

Table 6.1 R&D Pipeline for Anti-IBD Products, 2011

Table 7.1 SWOT Analysis of the World Inflammatory Bowel Disease Drug Market, 2011-2021

Table 8.1 Leading National Markets for IBD Treatments: Revenues ($m) and Market Shares (%), 2010, 2015 and 2021

Table 8.2 US IBD Drug Market Forecast ($m), 2010-2021

Table 8.3 Japanese IBD Drug Market Forecast ($m), 2010-2021

Table 8.4 German IBD Drug Market Forecast ($m), 2010-2021

Table 8.5 French IBD Drug Market Forecast ($m), 2010-2021

Table 8.6 Italian IBD Drug Market Forecast ($m), 2010-2021

Table 8.7 Spanish IBD Drug Market Forecast ($m), 2010-2021

Table 8.8 UK IBD Drug Market Forecast, ($m), 2010-2021

Table 8.9 IBD Drug Market in Top 5 EU Countries ($m), 2010-2021

Table 8.10 Chinese IBD Drug Market Forecast ($m), 2010-2021

Table 8.11 Indian IBD Drug Market Forecast ($m), 2010-2021

Table 8.12 IBD Drug Markets ($m) in the Two Leading Emerging Countries, 2010-2021

Table 8.13 IBD Drug Market in the Rest of the World ($m), 2010-2021

Table 8.14 Global IBD Market by Region: Revenues ($m) and Market Shares (%), 2010

Table 8.15 Leading National Market Forecasts for IBD Drugs ($m), 2010-2021

Table 9.1 Top Three Companies for IAIs: Revenues ($m) and Market Shares (%), 2010

Table 9.2 Warner Chilcott IBD Revenues ($m), 2010

Table 9.3 Shire Pharmaceuticals IBD Revenues ($m), 2010

Table 9.4 Prometheus Laboratories IBD Revenues ($m), 2010

Table 9.5 Diagnostic Tests for IBD Offered by Prometheus, 2011

List of Figures

Figure 2.1 Geographical Variations in the Incidence of IBD, 2010

Figure 3.1 Treatment Protocol for IBD, 2011

Figure 4.1 World IBD Drug Market Forecast ($m), 2010-2021

Figure 4.2 Crohn's Disease Market Forecast ($m), 2010-2021

Figure 4.3 Ulcerative Colitis Market Forecast ($m), 2010-2021

Figure 4.4 CD and UC Market Forecasts ($m), 2010-2021

Figure 4.5 UC and CD Market Shares (%), 2010

Figure 4.6 UC and CD Market Shares (%), 2015

Figure 4.7 UC and CD Market Shares (%), 2021

Figure 4.8 IBD Market Forecasts ($m) by Therapy Type, 2010-2021

Figure 4.9 IBD Drug Market Shares (%) By Therapy Type, 2010-2021

Figure 5.1 World Asacol Revenue Forecast ($m), 2010-2021

Figure 5.2 World Pentasa Revenue Forecast ($m), 2010-2021

Figure 5.3 World Entocort Revenue Forecast ($m), 2010-2021

Figure 5.4 World Lialda Revenue Forecast ($m), 2010-2021

Figure 5.5 World Salofalk Revenue Forecast ($m), 2010-2021

Figure 5.6 Market Forecast for Top IAI Drugs ($m), 2010-2021

Figure 5.7 World Remicade Revenue Forecast ($m), 2010-2021

Figure 5.8 World Humira Revenue Forecast ($m), 2010-2021

Figure 5.9 World Cimzia Revenue Forecast ($m), 2010-2021

Figure 5.10 World Tysabri Revenue Forecast ($m), 2010-2021

Figure 5.11 Market Forecasts for Top Biological IBD Drugs ($m), 2010-2021

Figure 8.1 National Market Shares (%), 2010

Figure 8.2 National Market Shares (%), 2015

Figure 8.3 National Market Shares (%), 2021

Figure 8.4 US IBD Drug Market Forecast ($m), 2010-2021

Figure 8.5 Japanese IBD Drug Market Forecast ($m), 2010-2021

Figure 8.6 US and Japanese IBD Drug Market Forecasts ($m), 2010-2021

Figure 8.7 IBD Drug Sales ($m) in Top 5 EU Countries, 2010-2021

Figure 8.8 IBD Drug Markets ($m) in the Two Leading Emerging Countries, 2010-2021

Figure 8.9 IBD Drug Market in the Rest of the World ($m), 2010-2021

Figure 8.10 Global IVD Market Shares (%) by Region, 2010

Figure 9.1 Top 3 Companies for IAIs: Market Shares (%), 2010

Companies Listed

Abbott Laboratories

Amalyte Pharmaceuticals

ARCA

AstraZeneca

Atlantic Pharmaceuticals

Biogen Idec

Cambridge Antibody Technology

Celltech Pharmaceuticals

Centocor Ortho Biotech

ChemoCentryx

Centre for Digestive Diseases, Sydney

China Medical

Cosmo Pharmaceuticals

Crohn's and Colitis Foundation of America

Crohn's and Colitis Foundation of Canada

Dr. Falk Pharma

Elan Corporation

Enzo Biochem

European Federation of Crohn's and Ulcerative Colitis Associations

European Medicines Agency (EMEA)

Evonik Industries

Ferring Pharmaceuticals

Food and Drug Administration (US FDA)

Giaconda

Giuliani

GlaxoSmithKline

Interneuron

Isis Pharmaceuticals

Johnson & Johnson

King's College London

Kyorin Pharmaceutical Co.

Medarex

Merck & Co.

Miltenyi Biotec

Nycomed

Otsuka Pharmaceutical Group

PDL BioPharma

Pfizer

Probiotic Therapy Research Centre, Sydney, Australia

Procter & Gamble Pharmaceuticals

Prometheus Laboratories

Protein Design Labs

Royalty Pharma

Salix Pharmaceuticals

Sanofi

Schering-Plough

Shire Pharmaceuticals Group

Takeda Pharmaceutical Company

Tillotts Pharma

UCB

University of Auckland, New Zealand

Warner Chilcott

World Gastroenterology Organisation

To order this report:

Drug and Medication Industry: Inflammatory Bowel Diseases: World Drug Market 2011-2021

Drug and Medication Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker